Ideal body weight (male) = 50 kg + 2.3 kg/in> 5 ft Ideal body weight (female) =45.5 kg+2.3 kg/in>5 ft Hypoparathyroidism and Addison's disease: a potentially lethal combination
Tables listed in Documenta Geigy also give desirable weights based on sex, height and frame size.
In our patient, the calculated surface area was 1.95m 2 and the cumulative dosage administered was therefore 241 mg/m", Using the above calculation, the ideal surface area would have been 1.4 m 2 , resulting in an approximate 30% reduction in dose. Further reduction might have been made in view of the abnormal liver function.
Case report
A 15-year-old schoolgirl was referred in 1980with predominantly gastrointestinal symptoms: weight loss, nausea, vomiting, diarrhoea with pale faeces, and vague central abdominal pain. She also complained of dizziness, 'funny turns' and breathlessness. Her supine BP was 100/70mmHg with a sinus tachycardia. She had been below the 3rd centile for her height since age 8 and for weigh t since age 12;she was prepubertal. of treatment she was admitted acutely with dyspnoea, orthopnoea and peripheral oedema. There was no preceding chest pain. The patient had by then received 470 mg doxorubicin (241mg/m").
Examination revealed a tachycardia of 120 per minute, elevation of the jugular venous pressure, cardiomegaly with a third heart sound, basal crepitations and sacral oedema. Chest X-ray confirmed cardiomegaly with left ventricular failure and an ECG showed new T-wave flattening throughout all leads. Serial ECGs and cardiac enzymes did not show the pattern associated with myocardial infarction. It was therefore concluded that this was a doxorubicininduced cardiomyopathy. The patient continued to deteriorate despite diuretic therapy and died 4 days after admission.
Discussion
This case history is disturbing because a patient who received cautious treatment with doxorubicin died of cardiac toxicity at a cumulative dose of only 241 mg/m 2 • The risk of cardiotoxicity with doxorubicin 2 is considered to increase from 3% at 400 mg/m 2 to 7% at 550 mg/m 2 and 18% at 700mg/m 2 • We consider that obese patients could develop cardiotoxicity if doses are calculated on the basis of total body weight because of the pharmacokinetics ofthe drug.
Our patient had deranged liver function tests before starting cytotoxic treatment, but the plasma bilirubin was normal. A 50% dose reduction is suggested when bilirubin levels exceed 1.2 mg/100 ml (20pmol/l)3, but no recommendations are made on the drug data sheet for dose reduction when there are liver enzyme abnormalities. Brenner et al." have shown that doxorubicin pharmacokinetics are unaffected by liver function abnormalities, although this does not exclude an effect upon tissue concentrations. In our patient the calculated dose was reduced from 117mg to 100mg as a precaution in view of the liver function abnormalities. We do not consider that the cardiotoxicity can be explained on liver function abnormalities alone, although they may have contributed to it.
In the obese patient the smaller ratio of body water and muscle mass to total body weight and the greater proportion of fat may lead to changes in the drug partitioning of polar lipid-insoluble drugs like doxorubicin. The drug has a high apparent volume of distribution (1780±1120l/m 2 ) 5, indicating that doxorubicin is concentrated in tissues as well as body water. Lee et al. 6 have shown that at 1.5 to 5 hours after an intravenous bolus of 30 mg/m 2 doxorubicin, the liver concentrates the drug most intensely (2.3-19.8pg/g), with lesser concentration occurring in tumour tissue, lymph nodes, muscle and bone marrow. Fat showed the lowest concentration of the drug (0.03-0.33Ilg/g). We suggest that in our obese patient, higher blood and heart levels of drug occurred because of a dosage calculation based on total body weight and hence an overestimation of total body water. Liver function abnormalities (which can occur in obesity without other pathology) may exacerbate this problem. We therefore suggest that since obesity is so common, doxorubicin and other lipid-insoluble drugs with a narrow therapeutic index should be administered on the basis of the patient's ideal surface area or weight.
Ideal body weight may be calculated using height and weight by Devine's 7 method:
Bone age was 12years. There were no other abnormal signs on examination and initial investigations were unhelpful: Hb 13.2g/100 ml, ESR 13mm/h, Na 133mmol/l, K 3.7 mmol/l, urea 4.9 mmol/l, liver function tests normal.
She had been investigated for similar symptoms one year earlier and no definite diagnosis had been reached, although her parents' divorce was thought to be a contributory factor. She had had a large number of problems during her life: febrile convulsions as an infant, asthma, recurrent respiratory tract infections, dysuria, joint swelling and tenderness, spontaneous bruising, cramps and diarrhoea. She had had three hospital admissions: infectious hepatitis (age 9), bronchitis (age 10) and abdominal pain and sickness (age 14).
Despite the suspicion of contributory social dysharmony, a presumptive diagnosis of inflammatory bowel disease was made and over a period of four weeks she underwent a number of investigations, including barium enema, barium meal and jejunal biopsy, all of which were normal. During this time her Hb fell to 7.6 g/l00 ml (normochromic, normocytic). Serum iron and folate were normal, while total and true cobalamins were elevated at 1370 and 1230ng/l respectively.
Hypocalcaemia was noted at the time of presentation (uncorrected serum Ca 1.8 mmol/l, albumin 38 gIl, non-fasting phosphate 2.55).Alkaline phosphatase was consistently normal ( < 180iu/l) and urinary Ca was low (0.09mmol/24 h). However, her serum calcium rose spontaneously over the next 25 days to 2.18 and 2.13mmol/l (corrected to albumin 40 gIl). She subsequently developed hyponatraemia (Na 127, 128mmol/l) with a tendency to hyperkalaemia (3.7, 4.8 mmolfl). Urea rose to 6.2 mmol/l, One month after her initial referral, Addison's disease was suspected and confirmed by a short Synacthen test (cortisol 69 and 55 nmol/l at 30and 60 min). Associated idiopathic hypoparathyroidism was also strongly suspected. Parathyroid hormone assay was not done.
While awaiting the results of the Synacthen test, treatment was commenced with intravenous saline, intravenous and oral hydrocortisone and oral fludrocortisone. After 24 hours treatment (total intravenous infusion 3.5 litres saline) she was much improved, but in view of her anaemia a decision was made to continue rehydration with whole blood. Transfusion was commenced. After 6 hours and during the second unit of blood she developed tight chest pain and breathlessness. There were clinical and radiological signs of pulmonary oedema. She was treated with antibiotics and diuretics and the transfusion was discontinued. However, she suffered a cardiac arrest S! hours after the start of the transfusion and although resuscitated she remained unconscious. On the next day her serum calcium was 1.77mmol/l, despite intravenous supplements. She was transferred to intensive care and electively ventilated, but died after 48 hours. Permission for postmortem examination was refused.
It is likely that the combination of Addison's disease and hypoparathyroidism was responsible for many of this patient's symptoms, particularly in the last year of her life. Her anaemia, which was otherwise unexplained, may also have been autoimmune (Blackfan-Diamond syndrome) but this is unproven.
In cases of idiopathic hypoparathyroidism in which Addison's disease supervenes, it is well established that the tendency to hypocalcaemia lessens 3 -s. This would explain the rise in serum calcium noted during the development of this patient's adrenocortical failure. The initial serum calcium of 1.84mmol/l was likely to be an underestimate of the severity of her parathyroid dysfunction. By the time that the Addisonian crisis was established, the almost normal calcium value was even more misleading.
The treatment of Addisonian crisis with corticosteroids, saline and blood may well have precipitated her fulminant pulmonary oedema by causing a catastrophic fall in ionized calcium. There are a number of possible mechanisms for such a fall. Glucocorticoids increase urinary calcium excretion in normal subjects, possibly by a renal mechanism", and fludrocortisone causes a calcium diuresis (in rats) when calcium absorption from the bowel is minimal", as in untreated hypoparathyroidism. In addition, volume repletion is associated with a reduction in sodiumlinked calcium reabsorption in the proximal renal tubule", and absorption in the distal tubule will have been minimal in the absence of parathyroid hormone. Finally, the administration of blood with its small content of unsaturated citrate may have exacerbated the situation.
The association of Addison's disease and hypoparathyroidism is not uncommon in young people", and a child or young adult who presents with an Addisonian crisis may well have undiagnosed idiopathic hypoparathyroidism. However, the diagnosis may not be obvious, as illustrated in this patient. The calcium should be determined as an emergency in every case. Ifthe corrected concentration is at or below the lower limit of normal, coincidental idiopathic hypoparathyroidism should be seriously considered. If diagnosed, it should be treated at the same time.
